GSK enters agreement to acquire IDRx Inc for up to $1.5 billion
LONDON: GSK plc (LSE/NYSE: GSK) and IDRx Inc. have entered into an agreement under which GSK will acquire IDRx, a Boston-based, clinical-stage biopharmaceutical company dedicated to developing precision therapeutics for the treatment of GIST. Under the agreement, GSK will pay…